Nurix Therapeutics earnings were -$207.3M for the trailing 12 months ending May 31, 2025, with N/A growth year over year. The latest NRIX earnings report on May 31, 2025 announced Q2 2025 earnings of -$43.5M, down 22.9% from last quarter. For the last reported fiscal year 2024 ending Nov 30, 2024, NRIX reported annual earnings of -$193.6M, with 34.5% growth. The next NRIX earnings date is Oct 9, 2025.
What were Nurix Therapeutics's earnings last quarter?
On NRIX's earnings call on Invalid Date, Nurix Therapeutics (NASDAQ: NRIX) reported Q2 2025 earnings per share (EPS) of -$0.52, up 26.76% year over year. Total NRIX earnings for the quarter were -$43.46 million. In the same quarter last year, Nurix Therapeutics's earnings per share (EPS) was -$0.71.
The next NRIX earnings date is Invalid Date. Add NRIX to your watchlist to be reminded of Nurix Therapeutics's next earnings date.
Is Nurix Therapeutics profitable or losing money?
As of the last Nurix Therapeutics earnings report, Nurix Therapeutics is currently losing money. Nurix Therapeutics's net profit (also called net income) for the twelve months ending May 31, 2025 was -$207.32 million, a 25.65% increase year over year.
What was NRIX's earnings growth in the past year?
As of Nurix Therapeutics's earnings date in Invalid Date, Nurix Therapeutics's earnings has grown year over year. NRIX earnings in the past year totalled -$207.32 million.
What are Nurix Therapeutics's earnings expectations?
The current EPS estimate for Nurix Therapeutics's earnings report in Invalid Date is -$0.83.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.